Stifel Nicolaus Has Lowered Expectations for Bicara Therapeutics (NASDAQ:BCAX) Stock Price

Bicara Therapeutics (NASDAQ:BCAX) had its price target dropped by equities researchers at Stifel Nicolaus from $45.00 to $43.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus‘s price target suggests a potential upside of 330.86% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. Mizuho raised their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 12th. Citigroup reissued a “market outperform” rating on shares of Bicara Therapeutics in a research report on Tuesday. HSBC lowered Bicara Therapeutics to an “equal weight” rating in a research note on Tuesday, September 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Thursday, September 10th. Finally, Wall Street Zen downgraded Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.75.

Bicara Therapeutics Trading Up 15.4%

NASDAQ BCAX opened at $9.98 on Tuesday. The firm has a market capitalization of $660.38 million, a P/E ratio of -3.22 and a beta of -0.33. The firm’s fifty day moving average price is $17.89 and its two-hundred day moving average price is $20.91. Bicara Therapeutics has a 1 year low of $7.87 and a 1 year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22). On average, research analysts anticipate that Bicara Therapeutics will post -3.49 EPS for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the sale, the chief executive officer directly owned 181,641 shares in the company, valued at $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BCAX. Sterling Capital Management LLC lifted its holdings in shares of Bicara Therapeutics by 457.0% during the third quarter. Sterling Capital Management LLC now owns 1,387 shares of the company’s stock worth $26,000 after buying an additional 1,138 shares in the last quarter. Profund Advisors LLC grew its stake in shares of Bicara Therapeutics by 7.2% in the third quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock valued at $314,000 after acquiring an additional 1,140 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Bicara Therapeutics by 15.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company’s stock valued at $224,000 after acquiring an additional 1,617 shares in the last quarter. Quantinno Capital Management LP grew its stake in shares of Bicara Therapeutics by 16.1% in the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after acquiring an additional 2,447 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics during the third quarter worth about $63,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.